Table 1:
Characteristics of study cohort at baselinea
| Standard Treatment Group (n = 180) | Intensive Treatment Group (n = 226) | |
|---|---|---|
| Follow-up period (median) (yr) | 3.86 | 3.82 |
| Age (yr) | 67.5 (SD, 8.4) | 68.4 (SD, 8.4) |
| Female sex (No.) (%) | 60 (33.3%) | 89 (39.4%) |
| Race (No.) (%) | ||
| White | 117 (65.0%) | 156 (69.0%) |
| Black | 51 (28.3%) | 59 (26.1%) |
| Hispanic | 9 (5.0%) | 7 (3.1%) |
| Other | 3 (1.7%) | 4 (1.8%) |
| SBP (mm Hg) | 139.6 (SD, 18.4) | 136.2 (SD, 18.2) |
| DBP (mm Hg) | 82.2 (SD, 13.2) | 80.2 (SD, 11.2) |
| eGFR (mL/min/1.73 m2) | 69.1 (SD, 21.3) | 65.2 (SD, 19.0) |
| Serum creatinine level (mg/dL) | 1.1 (SD, 0.4) | 1.1 (SD, 0.4) |
| Chronic kidney disease (eGFR <60 mL/min/1.73 m2) (No.) (%) | 61 (33.9) | 88 (38.9) |
| Framingham 10-year cardiovascular disease risk score (%) | 24.3 (SD, 12.4) | 23.5 (SD, 12.6) |
| TBV (cm3) | 1150.9 (SD, 117.0) | 1139.3 (SD, 117.3) |
| rTBV/ICV) | 0.82 (SD, 0.04) | 0.82 (SD, 0.04) |
| White matter lesion volume (median) (IQR) (cm3) | 1.6 (0.9–3.8) | 1.4 (0.6–3.6) |
Note:—DBP indicates diastolic blood pressure; IQR, interquartile range; eGFR, estimated glomerular rate; ICV, intracranial volume.
a
All values provided as means unless otherwise specified.